Fibroblast growth factor-23 (FGF-23) has demonstrated a strong association with RV dysfunction in both HFrEF and pulmonary hypertension, independently of congestion or BNP levels, and was associated with a risk of adverse outcomes [98,99]. Here, FGF23 is linked to pulmonary arterial hypertension.